A congressional sting operation has caught Coast IRB. The company approves clinical-trial designs and patient-safety guidelines but it appears their first concern is profit, not patient safety. Their work involves oversight of patient safety during clinical trials and they will now voluntarily halt many of their review operations at the request of the Food and Drug Administration according to the FDA. The action could affect 300 trials involving more than 3,000 researchers and includes work for several major pharmaceutical, biotechnology and medical-device companies.
It's about time somebody stepped up and started looking out for us!